Bioequivalence of generic cyclosporine

Generics/Research | Posted 29/04/2011 post-comment0 Post your comment

A clinical trial in allogeneic stem cell transplant (ASCT) recipients found that generic and branded cyclosporine could be considered interchangeable.

picture 89

Cyclosporine (or ciclosporin) is an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient’s immune system, and therefore the risk of organ rejection.

Bioequivalence of Equoral (generic cyclosporine, Teva) to Neoral solution (branded cyclosporine, Novartis) has been suggested by measurements of pharmacokinetic parameters in healthy volunteers and in stable renal transplant recipients, however had not been studied in ASCT recipients.

This study enrolled 30 ASCT patients in an open two-way cross-over design from June 2007 to November 2008, with a seven to 14-day test period for assessment of the pharmacokinetic parameters Cmax (extent of absorption), tmax (rate of absorption) and AUC0-12h (area under the concentration-time curve).

The pharmacokinetic parameters were found to be similar between the generic and branded versions and comparable toxicities and rates of graft-versus-host disease were recorded in both groups.

The authors therefore suggest that generic and branded cyclosporine can be considered interchangeable in ASCT recipients.

Reference

Tareka BO, Nadia BF, Anis K, et al. Assessment of bioequivalence of a generic cyclosporine (Equoral) by a prospective randomized controlled trial on allogeneic stem cell transplant recipients. Transplant Proc. 2010;42(9):3735-8.

comment icon Comments (0)
Post your comment
Related content
Pricing and reimbursement of medicines in Canada
79 MD002389
Generics/Research Posted 02/09/2022
Relevance of NTI to the treatment of epilepsy
Epileptic V16F10
Generics/Research Posted 01/07/2022
What is the meaning of a narrow therapeutic index?
05 AA011027
Generics/Research Posted 17/06/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010